Actionable news
All posts from Actionable news
Actionable news in OMED: OncoMed Pharmaceuticals, Inc.,

AbbVie to buy Stemcentrx in $5.8 billion deal


AbbVie Inc. agreed to acquire Stemcentrx in a roughly $5.8 billion cash-and-stock deal that expands its pipeline of cancer treatments.

With the acquisition, which includes additional potential milestone payments of as much as $4 billion, AbbVie ABBV, -1.45% gains Stemcentrx’s Rova-T lung cancer treatment, a biomarker-specific therapy that is derived...